• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal

    Simply Wall St·07/16/2026 14:28:32
    語音播報
    • Innovent Biologics recently announced an exclusive license agreement granting Spero Therapeutics rights to develop and commercialize IBI355 outside Greater China, with Innovent eligible for up to approximately US$1.10 billion in upfront and milestone payments plus tiered royalties.
    • The arrangement effectively turns IBI355 into a globally partnered asset, allowing Innovent to keep Greater China rights while leveraging Spero’s international development plans in IgG4-related disease and Sjögren’s disease.
    • We’ll now examine how this extensive licensing deal, and the potential US$1.10 billion in milestones, shapes Innovent Biologics’ investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    What Is Innovent Biologics' Investment Narrative?

    For Innovent, you really have to believe in the company as a China-based biologics platform that can repeatedly turn its R&D into partnered assets and royalty streams. The Spero deal around IBI355 fits neatly into that story, extending the recent run of global partnerships without changing the near term revenue or profit picture in a major way, given payments are heavily milestone based and clinical timelines stretch into 2027. In the short term, the more tangible catalysts still sit with late stage oncology programs like IBI343 and IBI3003, plus how effectively Innovent converts recent regulatory wins and NRDL inclusions into sustained product sales after its move into profitability. The flip side is execution risk around such a broad pipeline, especially after sizeable equity raises and insider selling.

    However, investors should also weigh how dependent the story is on partners actually delivering. Innovent Biologics' shares have been on the rise but are still potentially undervalued by 42%. Find out what it's worth.

    Exploring Other Perspectives

    SEHK:1801 1-Year Stock Price Chart
    SEHK:1801 1-Year Stock Price Chart
    Two Simply Wall St Community fair value views span roughly HK$117 to HK$163, suggesting very different expectations around Innovent’s partnered pipeline, while the Spero deal underlines how much rests on future milestone and royalty realization.

    Explore 2 other fair value estimates on Innovent Biologics - why the stock might be worth just HK$117.50!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.